Prevalence of dermatological complaints in patients undergoing treatment for breast cancer

Hoffmann, Tamara; Corrêa-Fissmer, Mariane; Duarte, Camila Soares; Nazário, Rayane Felippe; Barranco, Ana Beatriz Sanches; Oliveira, Karen Waleska Knipoff de

doi:10.1590/abd1806-4841.20186541

Cited by 7 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cutaneous adverse events can be a major problem, and may directly impact the QoL of patients receiving anticancer therapy. 22 , 23 A systematic review and meta-analysis reviewed the risk and incidence of pigmentary lesions, as adverse events, among 8052 patients treated with targeted therapy and enrolled in 36 clinical trials. In total, 17.7% of patients had depigmented skin lesions.…”

Section: Discussionmentioning

confidence: 99%

Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review

Sharaf¹,

AlMasri²,

Abdel-Razeq³

et al. 2022

CCID

View full text Add to dashboard Cite

Background: Cyclin-dependent kinase (CDK) 4/6 inhibitors have revolutionized the treatment landscape of hormone receptor-positive (HR + ), human epidermal growth factor receptor 2-negative (HER2 − ) metastatic breast cancer, with an impressive efficacy and safety profile. Cytopenia is the main adverse event, which is both predictable and manageable. Here, we report a case of CDK4/6 inhibitor-induced vitiligo-like lesions. Vitiligo or vitiligolike lesions are a rare adverse event; only a few cases are reported in the literature. Case Presentation: A 71-year-old female patient was diagnosed initially with early-stage right breast cancer (HR + /HER2 − ) and was treated with breast-conserving surgery followed by chemotherapy, radiotherapy, and hormonal therapy. A few years later, she developed metastatic disease to the hilar lymph nodes, and to multiple skeletal sites, including the left scapula, left shoulder, left iliac bone, and dorsal vertebrae, for which she was treated with ribociclib and letrozole. While on treatment, she developed hypopigmented lesions involving both hands, feet, and face, which were described as vitiligo-like lesions. Conclusion: CDK4/6 inhibitor-induced vitiligo is a rare and unpredictable adverse event. This case report highlights the rarity of this adverse event, the dilemma related to the optimal treatment, and decisions related to continuation, holding, or switching CDK4/6 inhibitors.

show abstract

Section: Discussionmentioning

confidence: 99%

Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review

Sharaf¹,

AlMasri²,

Abdel-Razeq³

et al. 2022

CCID

View full text Add to dashboard Cite

show abstract

“…Different studies were presented including disease related to the health status and toxicity of anticancer drugs for breast cancer patients 13,29,30. There are different combinations of chemotherapy for postoperative therapy in breast cancer,31 especially combinations of docetaxel with doxorubicin and doxorubicin with cyclophosphamide as the first line of chemotherapy in invasive breast cancer 32.…”

Section: Discussionmentioning

confidence: 99%

“…Different anticancer drugs are used to treat different types of tumors5 with drug categories6 affecting abnormal cells in many ways 7. A chemotherapy schedule entails a treatment regime of anticancer drugs that are given for a set time duration at repeated intervals, called chemotherapy cycles 7–13. Chemotherapy may be given on different schedules depending upon two major aspects.…”

Section: Introductionmentioning

confidence: 99%

Comparative study of adjuvant chemotherapeutic efficacy of docetaxel plus cyclophosphamide and doxorubicin plus cyclophosphamide in female breast cancer

Adeel

Asif

Faisal

et al. 2019

CMAR

View full text Add to dashboard Cite

PurposeThis retrospective study presents a comparative analysis of the overall survival and toxicities, as side effects, of docetaxel plus cyclophosphamide (TC) and doxorubicin plus cyclophosphamide (AC). The study measured their efficacies during adjuvant chemotherapy, treating Pakistani breast cancer patients by validating the results obtained, with the published analysis of the same treatment given to US patients.Patients and methodsBetween June 2015 and September 2017, for four chemotherapy cycles, 189 patients out of 358 received TC (75 mg/m2 of docetaxel, 600 mg/m2 of cyclophosphamide) and 169 were treated with AC (60 mg/m2 of doxorubicin, 600 mg/m2 of cyclophosphamide). On the basis of using pathological markers to assess patients, toxicities, as side effects, (due to docetaxel, doxorubicin, and cyclophosphamide) were listed in the database of this study. Common factors with respect to common terminology criteria for adverse events version 5.0 and side effects listed in MedlinePlus, NIH US database, and from the database of this study were then separated to be included in comparison for this study. Statistically, chi-squared test was used at α=0.05.ResultsThere was no statistically significant difference between the proportions of patients with vomiting, extreme tiredness, diarrhea, mild anemia, stability, and overall survival because P-value >0.05. However, AC remained less toxic (P-value <0.05) by 22.6%, 25.7%, 25.3%, 12.4%, 20.8%, and 16.4% compared to TC for changes in taste, muscle pain, burning hands, change in hemoglobin level, moderate anemia, and needing blood transfusion respectively, whereas TC remained less toxic by 52.9%, 32.5%, and 26.3% for dizziness, weight loss, and sores in throat and mouth, respectively.ConclusionAt 27 months, TC was more toxic than AC, whereas both combinations had the same overall survival rate.

show abstract

“…However, despite being the most established treatment modality for rooting out cancer, post-surgical complications such as dystrophic scars, hyperpigmentation, lymphoedema, and wound dehiscence have been commonly reported. [ 53 , 54 ] If surgery is combined with chemoradiation, complication rates shoot up to include infection and/or flap necrosis, surgical site infection, flap necrosis, late dehiscence after suture removal, epidermolysis, seroma, and hematoma. [ 55 ]…”

Section: Methodsmentioning

confidence: 99%

Dermatological Aspects of Nursing Oncology: Meaningful Observations Ensuring Better Quality of Life

Maheshwari

Shankar

Tyagi

et al. 2022

IJPC

View full text Add to dashboard Cite

Modern cancer management has changed over the period of time and now shifted to multidisciplinary care approach to ensure a better quality of life (QOL) of the surfing patients. Every form of cancer treatment has side effects and affects the QOL. Many of the side effects have been discussed in detail because of the need for timely interventions to prevent the consequences of the side effects. Dermatological adverse events due to cancer treatment are important but most commonly ignored in our clinical practice. Nursing staffs have a critical role in the early identification of such events and by briefing and training of the nursing staff in the identification of adverse events which can aid in the prevention of complications. As dermatologists may not be available round the clock, nursing staff are looking after the patients round the clock can prove very vital in screening cutaneous AE and adequately setting up referrals to aid early recognition and treatment of not only mild but also potentially life-threatening complications. The nursing staff, which is a cadre of health caregivers that are intimately involved in cancer care, can be trained to identify timely, skin-related adverse events. A literature search of scientific publications was done using the electronic databases PubMed, Science Direct, Cochrane Library, and Google Scholar. The search included terms ‘Adverse events (AEs) post-chemotherapy,’ ‘AE post-radiotherapy,’ ‘AE post-immunotherapy,’ ‘AE post-hormonal therapy for cancer’ and ‘AE post-cancer surgery.’ Data obtained from these studies and case reports were compiled and interpreted to prepare this review. This review focuses on various ways in which skin can be involved adversely as a part of cancer management and their classic and tell-tale signs to help the nurses in their better and quicker identification so that dermatologists are timely intimated and the treatment can be instituted to improve the patient’s QOL.

show abstract

Prevalence of dermatological complaints in patients undergoing treatment for breast cancer

Cited by 7 publications

References 30 publications

Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review

Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review

Comparative study of adjuvant chemotherapeutic efficacy of docetaxel plus cyclophosphamide and doxorubicin plus cyclophosphamide in female breast cancer

Dermatological Aspects of Nursing Oncology: Meaningful Observations Ensuring Better Quality of Life

Contact Info

Product

Resources

About